The same Capsugel deal today, Kravis said, would have a cost of capital near 9%, a reflection of the late-summer weakness in equity markets and window closing in the high-yield market, which moves on a hair trigger in turbulent times.
FORBES: KKR's Henry Kravis: 'Any Fool Can Buy A Company'